Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate sex differences in the effects of p35 reduction on biochemical pathways relevant to the modulation of Aβ plaque deposition and confirm the importance of examining both sexes in preclinical AD research.
|
31421203 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may contribute to Alzheimer's disease.
|
31068217 |
2019 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin-dependent kinase 5 (Cdk5), which binds to and is activated by p35, phosphorylates multiple substrates and plays an essential role in the development and function of the CNS; however, proteolytic production of p25 from p35 under stress conditions leads to the inappropriate activation of Cdk5 and contributes to hyperphosphorylation of τ and other substrates that are related to the pathogenesis of Alzheimer's disease.
|
28420695 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice.
|
21544067 |
2011 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This review focuses on the role of carotenoids like retinoic acid (RA), all trans retinoic acid (ATRA), lycopene and β-carotene in prevention of AD symptoms primarily through inhibition of amyloid beta (Aβ) formation, deposition and fibril formation either by reducing the levels of p35 or inhibiting corresponding enzymes.
|
21672580 |
2011 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we tested the early compensation hypothesis by analyzing the levels of p25 and its precursor p35 in AD postmortem samples from different brain regions at different stages of tau pathology, using quantitative Western blots.
|
21616478 |
2011 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The calpain-mediated cleavage of p35 to p25 and the resulting aberrant activity and neurotoxicity of Cdk5 have been implicated in neurological disorders, such as Alzheimer's disease.
|
21338355 |
2011 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The amount of p25, an aberrant cleavage product of p35 that activates cyclin-dependent kinase 5 (Cdk5), is elevated in AD brains.
|
20033852 |
2010 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Malfunctioning of cyclin-dependent kinase 5 (CDK5) through aberrant proteolytic cleavage of its neuronal activators p35 and p39 is involved in neurodegeneration in Alzheimer's disease (AD) and other neurodegenerative brain diseases.
|
15917097 |
2005 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cdk5 phosphorylates tau at AD-specific phospho-epitopes when it associates with p25. p25 is a truncated activator, which is produced from the physiological Cdk5 activator p35 upon exposure to Abeta peptides.
|
15592431 |
2005 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
|
14976144 |
2004 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Remarkably, concomitant overexpression of a 3'-UTR-truncated form of p35 promoted tumor growth in vivo and cell proliferation, cell-cycle progression, and cell survival in vitro.
|
28640256 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Data from genetic animal models suggest that in contrast to the central role of IL-12 for tumor immune-surveillance, its close relative IL-23 rather promotes tumor growth.
|
20603238 |
2010 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
One of them, in which the p40 and p35 form a covalent heterodimer and in which each subunit is fused to a molecule of scFv(L19), displays an excellent tumor targeting performance in vivo, as assessed by quantitative biodistribution analysis, and a potent anti-tumor effect, superior to the one of IL12-scFv(L19)-FLAG.
|
16823838 |
2006 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction analysis of tumor tissue demonstrated peak expression of IL-12 p35 and p40 at 48 h, which persisted up to 7 days.
|
16763609 |
2006 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Notably, retroviral transduction of tumor cells with p35 did not induce drug resistance, as shown by the absence of long-term tumor cell survival or detectable colony formation activity after CPA treatment.
|
12460909 |
2002 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In contrast, IL-12 p35 and IL-12 p40 were only rarely expressed in regressing Burkitt tumors.
|
11358987 |
2001 |
Neurodegenerative Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
Under neurotoxic conditions, p35 undergoes proteolytic cleavage to liberate p25, which has been implicated in various neurodegenerative diseases.
|
24725413 |
2014 |
Neurodegenerative Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
The activity of Cdk5 and its regulatory subunit p35 is thought to be important in both normal brain function and neurodegenerative disease pathogenesis.
|
21844361 |
2011 |
Neurodegenerative Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
It has been widely accepted that aberrant Cdk5 activity induced by the conversion of p35 to p25 plays roles in the pathogenesis of neurodegenerative diseases.
|
17979810 |
2007 |
Neurodegenerative Disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest that p35 transduction of neurons by viral vectors could be therapeutically useful in the treatment of human neurodegenerative diseases.
|
15307952 |
2004 |
Lupus Erythematosus, Systemic
|
0.030 |
Biomarker
|
disease |
BEFREE |
Analysis with PCR using the same primers on the chromosomal DNA showed that p35 gene was intact in SLE patients.
|
12472178 |
2003 |
Lupus Erythematosus, Systemic
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this experimental setting, we also demonstrated that IL-10-containing SLE PBMC supernatants inhibited IL-12 p35 and IL-12 p40 gene expression.
|
11014347 |
2000 |
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Using semiquantitative RT-PCR assay, it was shown that constitutive expression of IL-12 p35 gene is somewhat impaired in SLE compared with controls and that IL-12 p40 mRNA, which was present at low levels in controls, was undetectable in unstimulated SLE peripheral blood mononuclear cells (PBMC).
|
10525320 |
1999 |
Retinopathy of Prematurity
|
0.020 |
Biomarker
|
disease |
BEFREE |
The developmental cell death was slightly accelerated in ROP rats; however, no visible changes in the morphology of retinal layers were observed on P35.
|
31788758 |
2020 |